Anthony Polverino
Direttore/Membro del Consiglio presso BRAINSTORM CELL THERAPEUTICS INC.
Patrimonio netto: 12 643 $ in data 31/05/2024
Relazioni attive
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Irit Arbel | M | 64 | 24 anni | |
| Uri Yablonka | M | 47 | 10 anni | |
| Stacy Lindborg | M | 53 | 4 anni | |
| Troy Cox | M | 60 |
Zymeworks BC, Inc.
 Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | 5 anni |
| Alla Patlis | F | 37 | 12 anni | |
| Susan Mahony | M | 59 |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | 5 anni |
| Yael Gothelf | M | - | 17 anni | |
| Menghisteab Bairu | M | 63 | 3 anni | |
| Christopher Astle | M | 45 |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | 3 anni |
| Chaim Lebovits | M | 53 | 17 anni | |
| Kelvin Neu | M | 50 |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | 4 anni |
| Nir Naor | M | 49 | 1 anni | |
| Jacob Frenkel | M | 81 | 4 anni | |
| Bob Dagher | M | 55 | 1 anni | |
| Antal Pearl-Lendner | F | - | 2 anni | |
| Netta Blondheim-Shraga | M | - | 2 anni | |
| Kaycia Wilde | M | - |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | 3 anni |
| Yossef Levy | M | - | - | |
| Bruce Hart | M | 60 |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | 5 anni |
| Mary Kay Turner | F | - | 7 anni | |
| Mark Hollywood | M | 55 |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | 5 anni |
| Hartoun Hartounian | M | 62 | - | |
| Chris McDonald | M | - | 6 anni |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Ali Tehrani | M | 52 |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | 19 anni |
| Arie Belldegrun | M | 74 | 8 anni | |
| Ralph Kern | M | 67 | 6 anni | |
| Arturo O. Araya | M | 53 | 4 anni | |
| Nick Bedford | M | 64 |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | 16 anni |
| Preetam Shah | M | 51 | 2 anni | |
| David Tanen | M | 52 | - | |
| Elizabeth Faust | M | 59 | 2 anni | |
| Timothy Moore | M | 62 | 3 anni | |
| Ran Nussbaum | M | 51 | 4 anni | |
| Sankesh Abbhi | M | 38 | 1 anni | |
| Greg Mann | M | - | - | |
| Jonathan Peacock | M | 66 | 3 anni | |
| Claudine Prowse | M | - | - | |
| Paul L. Jenkinson | M | 64 | 1 anni | |
| Eyal Rubin | M | 48 | 2 anni | |
| Christine Cassiano | F | - | 1 anni | |
| David Bonderman | M | 81 | 6 anni | |
| Cynthia Butitta | F | 69 | 4 anni | |
| Joshua Kazam | M | 47 | 8 anni | |
| Malcolm Taub | M | 78 | 14 anni | |
| Robin Washington | F | 60 | - | |
| Franz Humer | M | 76 | 2 anni | |
| Ian Clark | M | 62 | - | |
| Farah Champsi | F | 62 | 4 anni | |
| Roy Doumani | M | 89 | 6 anni | |
| June Almenoff | M | 67 | 6 anni | |
| Steven Ruchefsky | M | 61 | 6 anni | |
| Bradley Glover | M | 55 | - | |
| Neil Josephson | M | - |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | 4 anni |
| Nadia Agopyan | M | 62 | 4 anni | |
| Kavita V. Shah | M | - |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | - |
| Kim Thacker | M | - | 2 anni | |
| David Setboun | M | 49 | 3 anni | |
| Anthony P Waclawski | M | 62 | 1 anni | |
| Jennifer Chow | F | - | - | |
| James Daniel Guylain Priour | M | 57 |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | - |
| Mary Klem | F | - |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | 2 anni |
| Sidney A. Spector | M | - | 2 anni | |
| Brian Sander | M | - | - | |
| Michele Korfin | F | 52 | 2 anni | |
| Roger Sidhu | M | 48 | 2 anni | |
| Kirk Taylor | M | - | - | |
| Kathryn O'Driscoll | F | 60 |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | 3 anni |
| Veer Bhavnagri | M | 41 | 4 anni | |
| Brett Pletcher | M | 56 | - | |
| Helen Kim | F | 61 | 4 anni | |
| Jason Okazaki | M | 48 | - | |
| Chen Schor | M | 51 | 9 anni | |
| Christopher Nowers | M | - | - | |
| John Smither | M | 71 | 1 anni | |
| Diana Hausman | M | 61 |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | 5 anni |
| Owen Witte | M | 74 | - | |
| Susan E. Ward | M | - | 2 anni | |
| Shawn Tomasello | F | 65 | 3 anni | |
| Wayne Godfrey | M | 63 | 1 anni | |
| Diane Parks | F | 71 | 2 anni | |
| Kimberly A. Metcalf | F | - | - | |
| Revital Geffen-Aricha | M | - | 7 anni | |
| Joseph Petroziello | M | - | 2 anni | |
| Guowei Fang | M | - |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | 2 anni |
Statistiche
| Paese | Relazioni | % del totale |
|---|---|---|
| Stati Uniti | 68 | 80.95% |
| Canada | 16 | 19.05% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Anthony Polverino
- Contatti personali
